InspireMD (NSPR) Stock Forecast: StockMap's 2-Week Call
NSPR stock forecast: StockMap's model leans Underperform on InspireMD for the two weeks after the Nov 19 close, toward NSPR trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 4 two-week windows on NSPR since Sep 24; by chance, a call on the same dates was right 54% of the time.
InspireMD last closed at $0.62, -10.14% on the session.
Against the IVW growth benchmark the position is -7.81% over the forecast window.
InspireMD's market cap is $33.35M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -24 (too close to call).
Where NSPR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
31 daily calls for NSPR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks InspireMD in the 8th percentile on return on equity, where 100 is best.
InspireMD is classified under Health Care / Health Care Equipment & Supplies.
StockMap tracks InspireMD as the 115th largest of the 141 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.
Across that group the current two-week reads are 69 Neutral, 55 Moderate Underperform, 14 Strong Underperform and 3 Moderate Outperform.
On that composite InspireMD ranks 85th of 141 in the group, against a group median of -0.18.